When Ariana Pharma announced this summer that the WIN Consortium had chosen it to develop new personalized cancer medicine software through the consortium’s WINTHER trial, it wasn’t just a validation of Paris-based Ariana’s data management skills in life science, notes Dr. David Morley, Ariana’s vice president of computational technology — it was also a sign of how much data mining has shifted from its early beginnings in drug discovery to something much more oriented toward clinical trials.

Read the full DDN News interview with David Morley online, or download the PDF (September 2013: Volume 9: Number 9: p15).

Links: Read online | Download PDF